{"id":"https://openalex.org/W2493897159","doi":"https://doi.org/10.1128/aac.00480-16","title":"HIV-1 Coinfection Does Not Reduce Exposure to Rifampin, Isoniazid, and Pyrazinamide in South African Tuberculosis Outpatients","display_name":"HIV-1 Coinfection Does Not Reduce Exposure to Rifampin, Isoniazid, and Pyrazinamide in South African Tuberculosis Outpatients","publication_year":2016,"publication_date":"2016-08-02","ids":{"openalex":"https://openalex.org/W2493897159","doi":"https://doi.org/10.1128/aac.00480-16","mag":"2493897159","pmid":"https://pubmed.ncbi.nlm.nih.gov/27480859","pmcid":"https://www.ncbi.nlm.nih.gov/pmc/articles/5038257"},"language":"en","primary_location":{"id":"doi:10.1128/aac.00480-16","doi":"https://doi.org/10.1128/aac.00480-16","is_oa":true,"landing_page_url":"https://doi.org/10.1128/aac.00480-16","pdf_url":null,"source":{"id":"https://openalex.org/S47215897","display_name":"Antimicrobial Agents and Chemotherapy","issn_l":"0066-4804","issn":["0066-4804","1070-6283","1098-6596"],"is_oa":false,"is_in_doaj":true,"is_core":true,"listed_in":["cwts-core","doaj","dongbi-b","doyens","jufo-3","ki-jl-2","medline","norway-2","poland-140","russia-white-list-1","vabb-shw"],"host_organization":"https://openalex.org/P4310320263","host_organization_name":"American Society for Microbiology","host_organization_lineage":["https://openalex.org/P4310320263"],"host_organization_lineage_names":["American Society for Microbiology"],"type":"journal"},"license":"cc-by","license_id":"https://openalex.org/licenses/cc-by","version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Antimicrobial Agents and Chemotherapy","raw_type":"journal-article"},"volume":null,"type":"article","is_traditional":true,"indexed_in":["crossref","doaj","pubmed"],"open_access":{"is_oa":true,"oa_status":"hybrid","oa_url":"https://doi.org/10.1128/aac.00480-16","any_repository_has_fulltext":true},"authorships":[{"author_position":"first","author":{"id":"https://openalex.org/A5012931164","display_name":"Neesha Rockwood","orcid":"https://orcid.org/0000-0002-7830-1394","observed_orcids":["https://orcid.org/0000-0002-7830-1394"]},"institutions":[{"id":"https://openalex.org/I157614274","display_name":"University of Cape Town","ror":"https://ror.org/03p74gp79","country_code":"ZA","type":"education","lineage":["https://openalex.org/I157614274"]},{"id":"https://openalex.org/I4405266898","display_name":"Institute of Infectious Disease and Molecular Medicine","ror":"https://ror.org/00900dw59","country_code":"ZA","type":"education","lineage":["https://openalex.org/I157614274","https://openalex.org/I4405266898"]},{"id":"https://openalex.org/I47508984","display_name":"Imperial College London","ror":"https://ror.org/041kmwe10","country_code":"GB","type":"education","lineage":["https://openalex.org/I47508984"]}],"countries":["GB","ZA"],"is_corresponding":false,"raw_author_name":"Neesha Rockwood","raw_affiliation_strings":["Clinical Infectious Diseases Research Initiative, Institute of Infectious Disease and Molecular Medicine, University of Cape Town, Cape Town, South Africa","Department of Medicine, Imperial College, London, United Kingdom"],"raw_orcid":"https://orcid.org/0000-0002-7830-1394","affiliations":[{"raw_affiliation_string":"Clinical Infectious Diseases Research Initiative, Institute of Infectious Disease and Molecular Medicine, University of Cape Town, Cape Town, South Africa","institution_ids":["https://openalex.org/I157614274","https://openalex.org/I4405266898"]},{"raw_affiliation_string":"Department of Medicine, Imperial College, London, United Kingdom","institution_ids":["https://openalex.org/I47508984"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5009435222","display_name":"Graeme Meintjes","orcid":"https://orcid.org/0000-0003-1196-4414","observed_orcids":["https://orcid.org/0000-0003-1196-4414"]},"institutions":[{"id":"https://openalex.org/I157614274","display_name":"University of Cape Town","ror":"https://ror.org/03p74gp79","country_code":"ZA","type":"education","lineage":["https://openalex.org/I157614274"]},{"id":"https://openalex.org/I4405266898","display_name":"Institute of Infectious Disease and Molecular Medicine","ror":"https://ror.org/00900dw59","country_code":"ZA","type":"education","lineage":["https://openalex.org/I157614274","https://openalex.org/I4405266898"]},{"id":"https://openalex.org/I47508984","display_name":"Imperial College London","ror":"https://ror.org/041kmwe10","country_code":"GB","type":"education","lineage":["https://openalex.org/I47508984"]}],"countries":["GB","ZA"],"is_corresponding":false,"raw_author_name":"Graeme Meintjes","raw_affiliation_strings":["Clinical Infectious Diseases Research Initiative, Institute of Infectious Disease and Molecular Medicine, University of Cape Town, Cape Town, South Africa","Department of Medicine, Imperial College, London, United Kingdom","Department of Medicine, University of Cape Town, Cape Town, South Africa"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Clinical Infectious Diseases Research Initiative, Institute of Infectious Disease and Molecular Medicine, University of Cape Town, Cape Town, South Africa","institution_ids":["https://openalex.org/I157614274","https://openalex.org/I4405266898"]},{"raw_affiliation_string":"Department of Medicine, Imperial College, London, United Kingdom","institution_ids":["https://openalex.org/I47508984"]},{"raw_affiliation_string":"Department of Medicine, University of Cape Town, Cape Town, South Africa","institution_ids":["https://openalex.org/I157614274"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5072683436","display_name":"Maxwell Chirehwa","orcid":"https://orcid.org/0000-0002-1685-4882","observed_orcids":["https://orcid.org/0000-0002-1685-4882"]},"institutions":[{"id":"https://openalex.org/I157614274","display_name":"University of Cape Town","ror":"https://ror.org/03p74gp79","country_code":"ZA","type":"education","lineage":["https://openalex.org/I157614274"]}],"countries":["ZA"],"is_corresponding":false,"raw_author_name":"Maxwell Chirehwa","raw_affiliation_strings":["Division of Clinical Pharmacology, Department of Medicine, University of Cape Town, Cape Town, South Africa"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Division of Clinical Pharmacology, Department of Medicine, University of Cape Town, Cape Town, South Africa","institution_ids":["https://openalex.org/I157614274"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5053945845","display_name":"Lubbe Wiesner","orcid":"https://orcid.org/0000-0002-9070-8699","observed_orcids":["https://orcid.org/0000-0002-9070-8699"]},"institutions":[{"id":"https://openalex.org/I157614274","display_name":"University of Cape Town","ror":"https://ror.org/03p74gp79","country_code":"ZA","type":"education","lineage":["https://openalex.org/I157614274"]}],"countries":["ZA"],"is_corresponding":false,"raw_author_name":"Lubbe Wiesner","raw_affiliation_strings":["Division of Clinical Pharmacology, Department of Medicine, University of Cape Town, Cape Town, South Africa"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Division of Clinical Pharmacology, Department of Medicine, University of Cape Town, Cape Town, South Africa","institution_ids":["https://openalex.org/I157614274"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5025069184","display_name":"Helen McIlleron","orcid":"https://orcid.org/0000-0002-0982-6226","observed_orcids":["https://orcid.org/0000-0002-0982-6226"]},"institutions":[{"id":"https://openalex.org/I157614274","display_name":"University of Cape Town","ror":"https://ror.org/03p74gp79","country_code":"ZA","type":"education","lineage":["https://openalex.org/I157614274"]}],"countries":["ZA"],"is_corresponding":false,"raw_author_name":"Helen McIlleron","raw_affiliation_strings":["Division of Clinical Pharmacology, Department of Medicine, University of Cape Town, Cape Town, South Africa"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Division of Clinical Pharmacology, Department of Medicine, University of Cape Town, Cape Town, South Africa","institution_ids":["https://openalex.org/I157614274"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5029089921","display_name":"Robert John Wilkinson","orcid":"https://orcid.org/0000-0002-2753-1800","observed_orcids":["https://orcid.org/0000-0002-2753-1800","https://orcid.org/0000-0001-8966-5217"]},"institutions":[{"id":"https://openalex.org/I157614274","display_name":"University of Cape Town","ror":"https://ror.org/03p74gp79","country_code":"ZA","type":"education","lineage":["https://openalex.org/I157614274"]},{"id":"https://openalex.org/I4405266898","display_name":"Institute of Infectious Disease and Molecular Medicine","ror":"https://ror.org/00900dw59","country_code":"ZA","type":"education","lineage":["https://openalex.org/I157614274","https://openalex.org/I4405266898"]},{"id":"https://openalex.org/I4405285715","display_name":"National Institute for Medical Research","ror":"https://ror.org/00146rb91","country_code":"GB","type":"facility","lineage":["https://openalex.org/I2801081054","https://openalex.org/I4210087105","https://openalex.org/I4405285715","https://openalex.org/I90344618"]},{"id":"https://openalex.org/I47508984","display_name":"Imperial College London","ror":"https://ror.org/041kmwe10","country_code":"GB","type":"education","lineage":["https://openalex.org/I47508984"]}],"countries":["GB","ZA"],"is_corresponding":false,"raw_author_name":"Robert J. Wilkinson","raw_affiliation_strings":["Clinical Infectious Diseases Research Initiative, Institute of Infectious Disease and Molecular Medicine, University of Cape Town, Cape Town, South Africa","Department of Medicine, Imperial College, London, United Kingdom","Department of Medicine, University of Cape Town, Cape Town, South Africa","Francis Crick Institute Mill Hill Laboratory, London, United Kingdom"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Clinical Infectious Diseases Research Initiative, Institute of Infectious Disease and Molecular Medicine, University of Cape Town, Cape Town, South Africa","institution_ids":["https://openalex.org/I157614274","https://openalex.org/I4405266898"]},{"raw_affiliation_string":"Department of Medicine, Imperial College, London, United Kingdom","institution_ids":["https://openalex.org/I47508984"]},{"raw_affiliation_string":"Department of Medicine, University of Cape Town, Cape Town, South Africa","institution_ids":["https://openalex.org/I157614274"]},{"raw_affiliation_string":"Francis Crick Institute Mill Hill Laboratory, London, United Kingdom","institution_ids":["https://openalex.org/I4405285715"]}]},{"author_position":"last","author":{"id":"https://openalex.org/A5056892721","display_name":"Paolo Denti","orcid":"https://orcid.org/0000-0001-7494-079X","observed_orcids":["https://orcid.org/0000-0001-7494-079X"]},"institutions":[{"id":"https://openalex.org/I157614274","display_name":"University of Cape Town","ror":"https://ror.org/03p74gp79","country_code":"ZA","type":"education","lineage":["https://openalex.org/I157614274"]}],"countries":["ZA"],"is_corresponding":true,"raw_author_name":"Paolo Denti","raw_affiliation_strings":["Division of Clinical Pharmacology, Department of Medicine, University of Cape Town, Cape Town, South Africa"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Division of Clinical Pharmacology, Department of Medicine, University of Cape Town, Cape Town, South Africa","institution_ids":["https://openalex.org/I157614274"]}]}],"institutions":[],"countries_distinct_count":2,"institutions_distinct_count":4,"corresponding_author_ids":["https://openalex.org/A5056892721"],"corresponding_institution_ids":["https://openalex.org/I157614274"],"apc_list":null,"apc_paid":null,"fwci":3.1094,"has_fulltext":false,"cited_by_count":34,"citation_normalized_percentile":{"value":0.91341126,"is_in_top_1_percent":false,"is_in_top_10_percent":true},"cited_by_percentile_year":{"min":88,"max":98},"biblio":{"volume":"60","issue":"10","first_page":"6050","last_page":"6059"},"is_retracted":false,"is_paratext":false,"is_xpac":false,"primary_topic":{"id":"https://openalex.org/T10038","display_name":"Tuberculosis Research and Epidemiology","score":0.7143999934196472,"subfield":{"id":"https://openalex.org/subfields/2725","display_name":"Infectious Diseases"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},"topics":[{"id":"https://openalex.org/T10038","display_name":"Tuberculosis Research and Epidemiology","score":0.7143999934196472,"subfield":{"id":"https://openalex.org/subfields/2725","display_name":"Infectious Diseases"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},{"id":"https://openalex.org/T10526","display_name":"HIV/AIDS drug development and treatment","score":0.14880000054836273,"subfield":{"id":"https://openalex.org/subfields/2725","display_name":"Infectious Diseases"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},{"id":"https://openalex.org/T10375","display_name":"Pharmacogenetics and Drug Metabolism","score":0.05429999902844429,"subfield":{"id":"https://openalex.org/subfields/3004","display_name":"Pharmacology"},"field":{"id":"https://openalex.org/fields/30","display_name":"Pharmacology, Toxicology and Pharmaceutics"},"domain":{"id":"https://openalex.org/domains/1","display_name":"Life Sciences"}}],"keywords":[{"id":"https://openalex.org/keywords/hiv-1-coinfection","display_name":"HIV-1 coinfection","score":0.9589999914169312},{"id":"https://openalex.org/keywords/tuberculosis","display_name":"tuberculosis","score":0.8640000224113464},{"id":"https://openalex.org/keywords/rifampicin","display_name":"rifampicin","score":0.9020000100135803},{"id":"https://openalex.org/keywords/isoniazid","display_name":"isoniazid","score":1.0},{"id":"https://openalex.org/keywords/pyrazinamide","display_name":"pyrazinamide","score":1.0},{"id":"https://openalex.org/keywords/antiretroviral-therapy","display_name":"antiretroviral therapy","score":0.9259999990463257},{"id":"https://openalex.org/keywords/lopinavir-ritonavir","display_name":"lopinavir/ritonavir","score":0.9629999995231628},{"id":"https://openalex.org/keywords/drug-drug-interactions","display_name":"drug-drug interactions","score":0.7770000100135803},{"id":"https://openalex.org/keywords/drug-clearance","display_name":"drug clearance","score":0.5680000185966492},{"id":"https://openalex.org/keywords/allometric-scaling","display_name":"allometric scaling","score":0.6850000023841858},{"id":"https://openalex.org/keywords/fat-free-mass","display_name":"fat-free mass","score":0.746999979019165},{"id":"https://openalex.org/keywords/adverse-drug-reactions","display_name":"adverse drug reactions","score":0.6890000104904175},{"id":"https://openalex.org/keywords/pulmonary-tuberculosis","display_name":"pulmonary tuberculosis","score":0.5249999761581421},{"id":"https://openalex.org/keywords/outpatients","display_name":"outpatients","score":0.6050000190734863}],"concepts":[{"id":"https://openalex.org/C2780459521","wikidata":"https://www.wikidata.org/wiki/Q417571","display_name":"Pyrazinamide","level":4,"score":0.9263861179351807},{"id":"https://openalex.org/C2776967927","wikidata":"https://www.wikidata.org/wiki/Q423169","display_name":"Isoniazid","level":3,"score":0.7588810920715332},{"id":"https://openalex.org/C71924100","wikidata":"https://www.wikidata.org/wiki/Q11190","display_name":"Medicine","level":0,"score":0.7468212246894836},{"id":"https://openalex.org/C112705442","wikidata":"https://www.wikidata.org/wiki/Q323936","display_name":"Pharmacokinetics","level":2,"score":0.6725006103515625},{"id":"https://openalex.org/C2779298103","wikidata":"https://www.wikidata.org/wiki/Q422618","display_name":"Ritonavir","level":5,"score":0.6386818885803223},{"id":"https://openalex.org/C2781069245","wikidata":"https://www.wikidata.org/wiki/Q12204","display_name":"Tuberculosis","level":2,"score":0.6125319600105286},{"id":"https://openalex.org/C2777288759","wikidata":"https://www.wikidata.org/wiki/Q4164182","display_name":"Dosing","level":2,"score":0.5531913042068481},{"id":"https://openalex.org/C126322002","wikidata":"https://www.wikidata.org/wiki/Q11180","display_name":"Internal medicine","level":1,"score":0.525741457939148},{"id":"https://openalex.org/C2778607973","wikidata":"https://www.wikidata.org/wiki/Q422652","display_name":"Rifampicin","level":3,"score":0.4851144552230835},{"id":"https://openalex.org/C98274493","wikidata":"https://www.wikidata.org/wiki/Q128406","display_name":"Pharmacology","level":1,"score":0.48212242126464844},{"id":"https://openalex.org/C2781413609","wikidata":"https://www.wikidata.org/wiki/Q7308373","display_name":"Regimen","level":2,"score":0.47309544682502747},{"id":"https://openalex.org/C2777813720","wikidata":"https://www.wikidata.org/wiki/Q1243018","display_name":"Coinfection","level":3,"score":0.4414086937904358},{"id":"https://openalex.org/C90924648","wikidata":"https://www.wikidata.org/wiki/Q120569","display_name":"Gastroenterology","level":1,"score":0.36199647188186646},{"id":"https://openalex.org/C142462285","wikidata":"https://www.wikidata.org/wiki/Q2528140","display_name":"Viral load","level":3,"score":0.19924652576446533},{"id":"https://openalex.org/C3013748606","wikidata":"https://www.wikidata.org/wiki/Q15787","display_name":"Human immunodeficiency virus (HIV)","level":2,"score":0.19872450828552246},{"id":"https://openalex.org/C203014093","wikidata":"https://www.wikidata.org/wiki/Q101929","display_name":"Immunology","level":1,"score":0.19278958439826965},{"id":"https://openalex.org/C2993143319","wikidata":"https://www.wikidata.org/wiki/Q583050","display_name":"Antiretroviral therapy","level":4,"score":0.15317121148109436},{"id":"https://openalex.org/C142724271","wikidata":"https://www.wikidata.org/wiki/Q7208","display_name":"Pathology","level":1,"score":0.05460992455482483}],"mesh":[{"descriptor_ui":"D000328","descriptor_name":"Adult","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D000995","descriptor_name":"Antitubercular Agents","qualifier_ui":"Q000097","qualifier_name":"blood","is_major_topic":false},{"descriptor_ui":"D000995","descriptor_name":"Antitubercular Agents","qualifier_ui":"Q000493","qualifier_name":"pharmacokinetics","is_major_topic":true},{"descriptor_ui":"D001682","descriptor_name":"Biological Availability","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D005260","descriptor_name":"Female","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D006801","descriptor_name":"Humans","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D007538","descriptor_name":"Isoniazid","qualifier_ui":"Q000097","qualifier_name":"blood","is_major_topic":false},{"descriptor_ui":"D007538","descriptor_name":"Isoniazid","qualifier_ui":"Q000493","qualifier_name":"pharmacokinetics","is_major_topic":true},{"descriptor_ui":"D008297","descriptor_name":"Male","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D009169","descriptor_name":"Mycobacterium tuberculosis","qualifier_ui":"Q000187","qualifier_name":"drug effects","is_major_topic":false},{"descriptor_ui":"D009169","descriptor_name":"Mycobacterium tuberculosis","qualifier_ui":"Q000254","qualifier_name":"growth & development","is_major_topic":false},{"descriptor_ui":"D010045","descriptor_name":"Outpatients","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D011446","descriptor_name":"Prospective Studies","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D011718","descriptor_name":"Pyrazinamide","qualifier_ui":"Q000097","qualifier_name":"blood","is_major_topic":false},{"descriptor_ui":"D011718","descriptor_name":"Pyrazinamide","qualifier_ui":"Q000493","qualifier_name":"pharmacokinetics","is_major_topic":true},{"descriptor_ui":"D012293","descriptor_name":"Rifampin","qualifier_ui":"Q000097","qualifier_name":"blood","is_major_topic":false},{"descriptor_ui":"D012293","descriptor_name":"Rifampin","qualifier_ui":"Q000493","qualifier_name":"pharmacokinetics","is_major_topic":true},{"descriptor_ui":"D013019","descriptor_name":"South Africa","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D014397","descriptor_name":"Tuberculosis, Pulmonary","qualifier_ui":"Q000097","qualifier_name":"blood","is_major_topic":false},{"descriptor_ui":"D014397","descriptor_name":"Tuberculosis, Pulmonary","qualifier_ui":"Q000188","qualifier_name":"drug therapy","is_major_topic":true},{"descriptor_ui":"D014397","descriptor_name":"Tuberculosis, Pulmonary","qualifier_ui":"Q000382","qualifier_name":"microbiology","is_major_topic":false},{"descriptor_ui":"D015233","descriptor_name":"Models, Statistical","qualifier_ui":null,"qualifier_name":null,"is_major_topic":true},{"descriptor_ui":"D015497","descriptor_name":"HIV-1","qualifier_ui":"Q000187","qualifier_name":"drug effects","is_major_topic":false},{"descriptor_ui":"D015497","descriptor_name":"HIV-1","qualifier_ui":"Q000502","qualifier_name":"physiology","is_major_topic":false},{"descriptor_ui":"D015658","descriptor_name":"HIV Infections","qualifier_ui":"Q000097","qualifier_name":"blood","is_major_topic":false},{"descriptor_ui":"D015658","descriptor_name":"HIV Infections","qualifier_ui":"Q000188","qualifier_name":"drug therapy","is_major_topic":false},{"descriptor_ui":"D015658","descriptor_name":"HIV Infections","qualifier_ui":"Q000821","qualifier_name":"virology","is_major_topic":false},{"descriptor_ui":"D019380","descriptor_name":"Anti-HIV Agents","qualifier_ui":"Q000627","qualifier_name":"therapeutic use","is_major_topic":true},{"descriptor_ui":"D019438","descriptor_name":"Ritonavir","qualifier_ui":"Q000627","qualifier_name":"therapeutic use","is_major_topic":false},{"descriptor_ui":"D019540","descriptor_name":"Area Under Curve","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D023241","descriptor_name":"Antiretroviral Therapy, Highly Active","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D060085","descriptor_name":"Coinfection","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D061466","descriptor_name":"Lopinavir","qualifier_ui":"Q000627","qualifier_name":"therapeutic use","is_major_topic":false}],"locations_count":6,"locations":[{"id":"doi:10.1128/aac.00480-16","doi":"https://doi.org/10.1128/aac.00480-16","is_oa":true,"landing_page_url":"https://doi.org/10.1128/aac.00480-16","pdf_url":null,"source":{"id":"https://openalex.org/S47215897","display_name":"Antimicrobial Agents and Chemotherapy","issn_l":"0066-4804","issn":["0066-4804","1070-6283","1098-6596"],"is_oa":false,"is_in_doaj":true,"is_core":true,"listed_in":["cwts-core","doaj","dongbi-b","doyens","jufo-3","ki-jl-2","medline","norway-2","poland-140","russia-white-list-1","vabb-shw"],"host_organization":"https://openalex.org/P4310320263","host_organization_name":"American Society for Microbiology","host_organization_lineage":["https://openalex.org/P4310320263"],"host_organization_lineage_names":["American Society for Microbiology"],"type":"journal"},"license":"cc-by","license_id":"https://openalex.org/licenses/cc-by","version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Antimicrobial Agents and Chemotherapy","raw_type":"journal-article"},{"id":"pmh:oai:europepmc.org:4015136","doi":null,"is_oa":true,"landing_page_url":"https://www.ncbi.nlm.nih.gov/pmc/articles/5038257","pdf_url":null,"source":{"id":"https://openalex.org/S4306400806","display_name":"Europe PMC (PubMed Central)","issn_l":null,"issn":null,"is_oa":false,"is_in_doaj":false,"is_core":false,"listed_in":[],"host_organization":"https://openalex.org/I1303153112","host_organization_name":"European Bioinformatics Institute","host_organization_lineage":["https://openalex.org/I1303153112"],"host_organization_lineage_names":[],"type":"repository"},"license":"cc-by","license_id":"https://openalex.org/licenses/cc-by","version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":null,"raw_type":"Text"},{"id":"pmh:oai:pubmedcentral.nih.gov:5038257","doi":null,"is_oa":true,"landing_page_url":"https://www.ncbi.nlm.nih.gov/pmc/articles/5038257","pdf_url":null,"source":{"id":"https://openalex.org/S2764455111","display_name":"PubMed Central","issn_l":null,"issn":null,"is_oa":true,"is_in_doaj":false,"is_core":false,"listed_in":[],"host_organization":"https://openalex.org/I1299303238","host_organization_name":"National Institutes of Health","host_organization_lineage":["https://openalex.org/I1299303238"],"host_organization_lineage_names":[],"type":"repository"},"license":"cc-by","license_id":"https://openalex.org/licenses/cc-by","version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Antimicrob Agents Chemother","raw_type":"Text"},{"id":"pmid:27480859","doi":null,"is_oa":false,"landing_page_url":"https://pubmed.ncbi.nlm.nih.gov/27480859","pdf_url":null,"source":{"id":"https://openalex.org/S4306525036","display_name":"PubMed","issn_l":null,"issn":null,"is_oa":false,"is_in_doaj":false,"is_core":false,"listed_in":[],"host_organization":"https://openalex.org/I1299303238","host_organization_name":"National Institutes of Health","host_organization_lineage":["https://openalex.org/I1299303238"],"host_organization_lineage_names":[],"type":"repository"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Antimicrobial agents and chemotherapy","raw_type":"Journal Article"},{"id":"pmh:oai:figshare.com:article/12943070","doi":null,"is_oa":true,"landing_page_url":"https://figshare.com/articles/journal_contribution/HIV-1_coinfection_does_not_reduce_exposure_to_rifampicin_isoniazid_and_pyrazinamide_in_South_African_tuberculosis_outpatients/12943070","pdf_url":null,"source":{"id":"https://openalex.org/S4377196282","display_name":"Figshare","issn_l":null,"issn":null,"is_oa":false,"is_in_doaj":false,"is_core":false,"listed_in":[],"host_organization":"https://openalex.org/I4210132348","host_organization_name":"Figshare (United Kingdom)","host_organization_lineage":["https://openalex.org/I4210132348"],"host_organization_lineage_names":[],"type":"repository"},"license":"cc-by","license_id":"https://openalex.org/licenses/cc-by","version":"submittedVersion","is_accepted":false,"is_published":false,"raw_source_name":"","raw_type":"Text"},{"id":"pmh:oai:spiral.imperial.ac.uk:10044/1/38666","doi":null,"is_oa":true,"landing_page_url":"http://hdl.handle.net/10044/1/38666","pdf_url":null,"source":{"id":"https://openalex.org/S4306401396","display_name":"Spiral (Imperial College London)","issn_l":null,"issn":null,"is_oa":false,"is_in_doaj":false,"is_core":false,"listed_in":[],"host_organization":"https://openalex.org/I47508984","host_organization_name":"Imperial College London","host_organization_lineage":["https://openalex.org/I47508984"],"host_organization_lineage_names":[],"type":"repository"},"license":"other-oa","license_id":"https://openalex.org/licenses/other-oa","version":"submittedVersion","is_accepted":false,"is_published":false,"raw_source_name":"6059","raw_type":"Journal Article"}],"best_oa_location":{"id":"doi:10.1128/aac.00480-16","doi":"https://doi.org/10.1128/aac.00480-16","is_oa":true,"landing_page_url":"https://doi.org/10.1128/aac.00480-16","pdf_url":null,"source":{"id":"https://openalex.org/S47215897","display_name":"Antimicrobial Agents and Chemotherapy","issn_l":"0066-4804","issn":["0066-4804","1070-6283","1098-6596"],"is_oa":false,"is_in_doaj":true,"is_core":true,"listed_in":["cwts-core","doaj","dongbi-b","doyens","jufo-3","ki-jl-2","medline","norway-2","poland-140","russia-white-list-1","vabb-shw"],"host_organization":"https://openalex.org/P4310320263","host_organization_name":"American Society for Microbiology","host_organization_lineage":["https://openalex.org/P4310320263"],"host_organization_lineage_names":["American Society for Microbiology"],"type":"journal"},"license":"cc-by","license_id":"https://openalex.org/licenses/cc-by","version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Antimicrobial Agents and Chemotherapy","raw_type":"journal-article"},"sustainable_development_goals":[{"score":1.0,"id":"https://metadata.un.org/sdg/3","display_name":"Good health and well-being"}],"study_designs":[{"id":"https://openalex.org/study-designs/observational-study","display_name":"Observational Study"}],"awards":[{"id":"https://openalex.org/G2006052962","display_name":null,"funder_award_id":"10218","funder_id":"https://openalex.org/F4320312060","funder_display_name":"Francis Crick Institute"},{"id":"https://openalex.org/G2120397826","display_name":null,"funder_award_id":"UID 85858","funder_id":"https://openalex.org/F4320320671","funder_display_name":"National Research Foundation"},{"id":"https://openalex.org/G2549977564","display_name":"Defining interventions to reduce mortality in severe HIV-associated tuberculosis.","funder_award_id":"098316","funder_id":"https://openalex.org/F4320311904","funder_display_name":"Wellcome Trust"},{"id":"https://openalex.org/G2560876791","display_name":null,"funder_award_id":"90729","funder_id":"https://openalex.org/F4320320671","funder_display_name":"National Research Foundation"},{"id":"https://openalex.org/G2919344005","display_name":null,"funder_award_id":"96841","funder_id":"https://openalex.org/F4320320671","funder_display_name":"National Research Foundation"},{"id":"https://openalex.org/G3222167927","display_name":null,"funder_award_id":"WT 084323","funder_id":"https://openalex.org/F4320311904","funder_display_name":"Wellcome Trust"},{"id":"https://openalex.org/G374462724","display_name":"Host directed therapies against tuberculosis.","funder_award_id":"104803/Z/14/Z","funder_id":"https://openalex.org/F4320311904","funder_display_name":"Wellcome Trust"},{"id":"https://openalex.org/G4883735725","display_name":null,"funder_award_id":"WT104803","funder_id":"https://openalex.org/F4320311904","funder_display_name":"Wellcome Trust"},{"id":"https://openalex.org/G4977597969","display_name":null,"funder_award_id":"UKMRC U1175.02.002.00014","funder_id":"https://openalex.org/F4320334626","funder_display_name":"Medical Research Council"},{"id":"https://openalex.org/G5782876996","display_name":"Host directed therapies against tuberculosis.","funder_award_id":"104803","funder_id":"https://openalex.org/F4320311904","funder_display_name":"Wellcome Trust"},{"id":"https://openalex.org/G6086077386","display_name":"International Maternal Pediatric Adolescent AIDS Clinical Trials (IMPAACT) Group","funder_award_id":"U01AI068632","funder_id":"https://openalex.org/F4320337355","funder_display_name":"National Institute of Allergy and Infectious Diseases"},{"id":"https://openalex.org/G7322909815","display_name":null,"funder_award_id":"64787","funder_id":"https://openalex.org/F4320320671","funder_display_name":"National Research Foundation"},{"id":"https://openalex.org/G76681233","display_name":null,"funder_award_id":"84323","funder_id":"https://openalex.org/F4320311904","funder_display_name":"Wellcome Trust"},{"id":"https://openalex.org/G9000863735","display_name":"Advancing Clinical Therapeutics Globally for HIV/AIDS and Other Infections","funder_award_id":"UM1AI068636","funder_id":"https://openalex.org/F4320337355","funder_display_name":"National Institute of Allergy and Infectious Diseases"},{"id":"https://openalex.org/G9000884504","display_name":"AIDS Clinical Trial Group Laboratory Center","funder_award_id":"UM1AI106701","funder_id":"https://openalex.org/F4320337355","funder_display_name":"National Institute of Allergy and Infectious Diseases"},{"id":"https://openalex.org/G9000886520","display_name":"Statistical and Data Management Center (SDMC), Advancing Clinical Therapeutics Globally for HIV/AIDS and Other Infections (ACTG)","funder_award_id":"UM1AI068634","funder_id":"https://openalex.org/F4320337355","funder_display_name":"National Institute of Allergy and Infectious Diseases"}],"funders":[{"id":"https://openalex.org/F4320311904","display_name":"Wellcome Trust","ror":"https://ror.org/029chgv08"},{"id":"https://openalex.org/F4320312060","display_name":"Francis Crick Institute","ror":"https://ror.org/04tnbqb63"},{"id":"https://openalex.org/F4320320671","display_name":"National Research Foundation","ror":"https://ror.org/05s0g1g46"},{"id":"https://openalex.org/F4320334626","display_name":"Medical Research Council","ror":"https://ror.org/03x94j517"},{"id":"https://openalex.org/F4320337355","display_name":"National Institute of Allergy and Infectious Diseases","ror":"https://ror.org/043z4tv69"}],"has_content":{"pdf":false,"grobid_xml":false},"content_urls":null,"referenced_works_count":43,"referenced_works":["https://openalex.org/W233147817","https://openalex.org/W1489900818","https://openalex.org/W1965987183","https://openalex.org/W1968194776","https://openalex.org/W1968940867","https://openalex.org/W1971385179","https://openalex.org/W1972438261","https://openalex.org/W1989148061","https://openalex.org/W1989525615","https://openalex.org/W1995803983","https://openalex.org/W2006392678","https://openalex.org/W2011120498","https://openalex.org/W2011863437","https://openalex.org/W2012393743","https://openalex.org/W2021702829","https://openalex.org/W2039786149","https://openalex.org/W2061399828","https://openalex.org/W2062243603","https://openalex.org/W2065039877","https://openalex.org/W2082262203","https://openalex.org/W2089176235","https://openalex.org/W2097210644","https://openalex.org/W2098049342","https://openalex.org/W2100724974","https://openalex.org/W2105544821","https://openalex.org/W2107834145","https://openalex.org/W2113719939","https://openalex.org/W2119593718","https://openalex.org/W2120416054","https://openalex.org/W2139724863","https://openalex.org/W2141228465","https://openalex.org/W2144692033","https://openalex.org/W2147213334","https://openalex.org/W2148981816","https://openalex.org/W2160753277","https://openalex.org/W2163094860","https://openalex.org/W2164438043","https://openalex.org/W2170012142","https://openalex.org/W2170452898","https://openalex.org/W2336896130","https://openalex.org/W2411171235","https://openalex.org/W3009705041","https://openalex.org/W4399523345"],"related_works":["https://openalex.org/W3205522338","https://openalex.org/W2556647624","https://openalex.org/W2138753225","https://openalex.org/W4413814882","https://openalex.org/W1922118029","https://openalex.org/W209232424","https://openalex.org/W4310211489","https://openalex.org/W2089176235","https://openalex.org/W2145644454","https://openalex.org/W1989948347"],"abstract_inverted_index":{"There":[0],"are":[1],"contrasting":[2],"data":[3],"in":[4,12,24,161],"the":[5,17,34,57,69,147,179,204,225,230],"literature":[6],"about":[7],"antituberculosis":[8,52,60,241],"plasma":[9,92],"drug":[10,61,65,160,242],"concentrations":[11,62,93,158,243],"HIV-1-coinfected":[13,125,228],"patients.":[14,247],"We":[15,54],"report":[16],"pharmacokinetics":[18],"of":[19,27,36,50,99,159,187,199,209,221,232],"rifampin,":[20,88],"isoniazid,":[21,89],"and":[22,42,63,90,135,156,177],"pyrazinamide":[23,91],"a":[25,100,197],"cohort":[26],"patients":[28,75,126],"being":[29],"treated":[30],"for":[31,117,131,203,218],"active":[32],"tuberculosis,":[33],"majority":[35,231],"whom":[37,233],"were":[38,83,115,234],"coinfected":[39,80],"with":[40,76,81,142,196],"HIV-1":[41],"had":[43,127],"commenced":[44],"antiretroviral":[45],"therapy":[46,165],"within":[47],"2":[48],"months":[49],"starting":[51],"treatment.":[53],"also":[55],"examined":[56],"association":[58],"between":[59],"reported":[64],"side":[66],"effects":[67],"at":[68],"2-month":[70],"clinical":[71],"review.":[72],"One":[73],"hundred":[74],"pulmonary":[77],"tuberculosis":[78],"(65%":[79],"HIV-1)":[82],"intensively":[84],"sampled":[85],"to":[86,96,106,152,214,245],"determine":[87],"after":[94],"7":[95],"8":[97],"weeks":[98],"daily":[101],"quadruple-therapy":[102],"regimen":[103],"dosed":[104],"according":[105],"World":[107],"Health":[108],"Organization":[109],"(WHO)":[110],"weight":[111,192,206,217],"bands.":[112],"Pharmacokinetic":[113],"parameters":[114],"determined":[116],"each":[118],"patient":[119],"by":[120,175],"using":[121],"nonlinear":[122],"mixed-effects":[123],"models.":[124],"lower":[128],"clearance":[129,222],"rates":[130],"rifampin":[132,173],"(21%":[133],"decrease)":[134,138],"isoniazid":[136],"(23%":[137],"than":[139],"HIV-1-uninfected":[140,246],"patients,":[141,229],"resulting":[143],"higher":[144],"areas":[145],"under":[146],"concentration-time":[148],"curve":[149],"from":[150],"0":[151],"24":[153],"h":[154],"(AUC0-24)":[155],"maximum":[157],"serum":[162],"(Cmax).":[163],"Antiretroviral":[164],"(ART)":[166],"that":[167],"included":[168],"double-standard-dose":[169],"lopinavir/ritonavir":[170],"further":[171],"lowered":[172],"clearance,":[174],"46%,":[176],"increased":[178],"AUC0-24":[180],"The":[181],"current":[182],"uniform":[183],"dosing":[184],"(per":[185],"kilogram":[186],"body":[188,216],"weight)":[189],"across":[190],"WHO":[191],"bands":[193],"was":[194],"associated":[195],"trend":[198],"decreased":[200],"pharmacokinetic":[201],"exposures":[202],"lowest":[205],"band.":[207],"Use":[208],"fat-free":[210],"mass":[211],"as":[212],"opposed":[213],"total":[215],"allometric":[219],"scaling":[220],"significantly":[223],"improved":[224],"model.":[226],"Ambulant":[227],"coprescribed":[235],"ART,":[236],"did":[237],"not":[238],"have":[239],"reduced":[240],"compared":[244]},"counts_by_year":[{"year":2026,"cited_by_count":2},{"year":2025,"cited_by_count":1},{"year":2024,"cited_by_count":6},{"year":2023,"cited_by_count":6},{"year":2022,"cited_by_count":3},{"year":2021,"cited_by_count":3},{"year":2020,"cited_by_count":1},{"year":2019,"cited_by_count":5},{"year":2018,"cited_by_count":4},{"year":2017,"cited_by_count":3}],"updated_date":"2026-11-07T11:25:07.637180","created_date":"2016-08-23T00:00:00"}